Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
View Patent ↗The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method for diagnosing a human as having an increased risk for psoriasis, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene SLC22A4 as represented by position 101 of SEQ ID NO: 108 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to G at said position 101 of SEQ ID NO: 108 or C at said complement, wherein the nucleotide sequence of said oligonucleotide consists of a segment of at least 12 contiguous nucleotides of SEQ ID NO: 108 or its complement and includes said position 101;
b) detecting the presence of said G or said C in said nucleic acid;
c) diagnosing said human as having an increased risk for psoriasis due to the presence of said G or said C; and
d) administering a therapeutic agent suitable for prevention or treatment of psoriasis to said human.
2. A method for diagnosing a human as having an increased risk for psoriasis, the method comprising:
a) amplifying by polymerase chain reaction (PCR) a fragment of nucleic acid from said human that includes a polymorphism in gene SLC22A4 as represented by position 101 of SEQ ID NO: 108 or its complement to thereby create an amplicon containing said polymorphism;
b) testing for said polymorphisms by contacting said amplicon with an oligonucleotide that specifically hybridizes to G at said position 101 of SEQ ID NO: 108 or C at said complement, wherein the nucleotide sequence of said oligonucleotide consists of a segment of at least 12 contiguous nucleotides of SEQ ID NO: 108 or its complement and includes said position 101;
c) detecting the presence of said G or said C;
d) diagnosing said human as having an increased risk for psoriasis due to the presence of said G or said C; and
e) administering a therapeutic agent suitable for prevention or treatment of psoriasis to said human.
3. A method for diagnosing a human as having an increased risk for psoriasis, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene SLC22A4 as represented by position 101 of SEQ ID NO: 108 or its complement by contacting said nucleic acid with an oligonucleotide that hybridizes 5′ of said polymorphism, a polymerase, and at least one dideoxynucleotide triphosphate (ddNTP) selected from the group consisting of ddGTP and ddCTP;
b) extending said oligonucleotide to said position 101 of SEQ ID NO: 108 or its complement, wherein said extending comprises incorporating said ddNTP into the 3′ end of said oligonucleotide when said 3′ end reaches said position to thereby terminate said extending;
c) detecting the presence of G at said position 101 of SEQ ID NO: 108 or C at said complement by detecting said ddNTP;
d) diagnosing said human as having an increased risk for psoriasis due to the presence of said G or said C; and
e) administering a therapeutic agent suitable for prevention or treatment of psoriasis to said human.
4. The method of claim 1 , wherein said method comprises nucleic acid amplification by polymerase chain reaction (PCR).
5. The method of claim 1 , wherein said testing comprises allele-specific amplification, and further wherein the presence of said G or said C is detected by detecting the presence of an amplicon.
6. The method of claim 1 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
7. The method of claim 2 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
8. The method of claim 1 , wherein said oligonucleotide is an allele-specific probe.
9. The method of claim 1 , wherein said oligonucleotide is an allele-specific primer.
10. The method of claim 2 , wherein said oligonucleotide is an allele-specific probe.
11. The method of claim 1 , wherein said oligonucleotide is an allele-specific primer comprising SEQ ID NO: 133.
12. The method of claim 1 , wherein said human is homozygous for said G or said C.
13. The method of claim 1 , wherein said human is heterozygous for said G or said C.
14. The method of claim 2 , wherein said human is homozygous for said G or said C.
15. The method of claim 2 , wherein said human is heterozygous for said G or said C.
16. The method of claim 3 , wherein said human is homozygous for said G or said C.
17. The method of claim 3 , wherein said human is heterozygous for said G or said C.
18. The method of claim 3 , wherein said ddNTP is detectably labeled with a fluorescent dye.
19. The method of claim 3 , wherein said ddNTP is detectably labeled with a mass tag.
20. The method of claim 3 , wherein the 3′ end of said oligonucleotide hybridizes to the nucleotide immediately 5′ of said polymorphism, and said extending comprises extension by a single nucleotide whereby only said ddNTP is incorporated into the 3′ end of said oligonucleotide.
21. The method of claim 3 , further comprising contacting said nucleic acid with deoxynucleotide triphosphates (dNTPs).
22. The method of claim 3 , wherein said method comprises nucleic acid sequencing.
23. The method of claim 3 , wherein said method comprises nucleic acid amplification by polymerase chain reaction (PCR).
24. The method of claim 1 , wherein said human does not have psoriasis at the time of said testing.